Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9681520 | 0.89 | NPC1 (0.58) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL15169106 | 0.85 | ALDH1A1 (0.47) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL19834496 | 0.82 | ACACA (0.48) | MAPTTHRBKMT2A | |
| SCHEMBL509170 | 0.82 | MAPT (0.47) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL15754826 | 0.81 | NPC1 (0.60) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL14710238 | 0.81 | CA12 (0.48) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL19834374 | 0.81 | NPC1 (0.46) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL15754911 | 0.81 | NPC1 (0.60) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL14152567 | 0.81 | NPC1 (0.43) | NPC1RAB9AKDM4EMAPTHPGD | |
| SCHEMBL12571512 | 0.80 | MAPK1 (0.50) | NPC1RAB9AKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292577-B1 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO CELTIQUE SA (LU) | 2012-10-24 | — | — | EP | disclosed |
| CN-1321112-C | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker | EURO CELTIQUE SA (LU) | 2007-06-13 | — | — | CN | disclosed |
| US-7078426-B2 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-07-18 | — | — | US | disclosed |
| US-6919363-B2 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-07-19 | — | — | US | disclosed |
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. | 2004-01-01 | — | — | US | disclosed |
| CN-1422257-A | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker | EURO CELTIQUE SA (LU) | 2003-06-04 | — | — | CN | disclosed |
| EP-1292577-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | Euro-Celtique S.A. (LU) | 2003-03-19 | — | — | EP | disclosed |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | PURDUE PHARMA L.P. | 2002-01-17 | — | — | US | disclosed |
| WO-2001072714-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO-CELTIQUE S.A. (LU) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | CACNA1I, GRIK5, SOD1 | NPC1 2494/4885RAB9A 3481/4885KDM4E 3325/4885 |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | GRIK5, CACNA1I, SOD1 | NPC1 2641/4885RAB9A 3365/4885KDM4E 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.